Potent & effective
Induction of a strong cytotoxic immune response directed against a selection of tumour antigens
Scalable & convenient
Simple production of a large quantity of a highly qualified off-the-shelf product
Versatile & applicable to any cancers
The peptides can easily be changed to target a specific cancer type
Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).
However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).
Lung Cancer, Non-Small Cell,
1.8 million new cases of lung cancer were diagnosed worldwide in 2012, and this disease was responsible for and 1.6 million deaths. Lung cancer is therefore the most frequently diagnosed cancer and the leading cause of cancer mortality.
About 40% of patients are diagnosed with locally advanced (stage IIIb) or metastatic (stage IV) cancer; prognosis is poor (median survival 8-13 months).
Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a clinical-stage biotech company that develops a new class of antigen – specific active immunotherapies based on a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line).
PDC*mel, our leading drug candidate is currently in phase 1 clinical trials for melanoma. PDC*lung is in preclinical development for lung cancer.